M. Tonini

[5alpha-reductase type 2 deficiency: experiences from Campinas (SP) and Salvador (BA)].

D. Damiani, G. Guerra‐Júnior, M. Toralles, 2005, Arquivos brasileiros de endocrinologia e metabologia.

Facioscapulohumeral (FSHD1) and other forms of muscular dystrophy in the same family: is there more in muscular dystrophy than meets the eye?

M. Passos-Bueno, M. Zatz, V. Dubowitz, 2002, Neuromuscular Disorders.

Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD)

M. Passos-Bueno, M. Zatz, S. R. Matioli, 2004, Neuromuscular Disorders.

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

L. N. Valenti, C. Trautwein, S. Cockell, 2021, JHEP reports : innovation in hepatology.

Equal proportions of affected cells in muscle and blood of a mosaic carrier of facioscapulohumeral muscular dystrophy

M. Zatz, R. Frants, R. Lemmers, 2006, Human Genetics.

Homozygosity for autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) does not result in a more severe phenotype

M. Zatz, S. M. van der Maarel, J. Gurgel-Giannetti, 2004, Journal of Medical Genetics.

New mutations, hotspots, and founder effects in Brazilian patients with steroid 5α-reductase deficiency type 2

L. E. Oliveira, Luiz E. Oliveira, G. Guerra‐Júnior, 2005, Journal of Molecular Medicine.

Homozygosity for autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) does not result in a more severe phenotype

R. Lemmers, J. Gurgel-Giannetti, R. Frants, 2004, Journal of Medical Genetics.